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cruited to investigate the effect of a single treatment with 
the test emollient on the molecular structure of the skin bar-
rier at greater depths by employing the tape-stripping tech-
nique. The test emollient hydrated the skin to a significantly 
greater extent and for a longer period of time compared to 
the control emollient, an effect associated with a significant 
elevation of carboxylate groups (a marker of natural moistur-
izing factor content) within the stratum corneum. Further-
more, the test emollient imparted additional benefits to the 
structure and function of the skin barrier not exhibited by 
the control emollient. In conclusion, the test emollient ad-
dressed the pathological features of xerotic aged skin, sup-
porting its use as first-line therapy for xerotic skin conditions 
in this population.  © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Worldwide the prevalence of xerosis increases with 
advancing age, affecting up to 75% of older people  [1] . 
The development of xerotic conditions, such as atopic 
dermatitis (AD), asteatotic eczema and winter xerosis, is 
associated with a skin barrier defect. This defect is char-
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 Abstract 
 Xerosis affects up to 75% of older people and develops as a 
result of a skin barrier defect. Emollients are widely used to 
treat xerosis; however, there is limited understanding of the 
differences between them and their effects on the skin bar-
rier in older people. This study aimed to compare the effect 
of a commercially available emollient containing 5% urea, 
ceramide NP and lactate (test emollient) to an alternative 
emollient without these additives (control emollient) on the 
properties of the skin barrier in older people. Two cohorts of 
21 volunteers aged >60 years with dry skin were recruited. 
The first applied the test emollient to one forearm and no 
treatment to the other for 28 days. The second compared the 
test emollient to the control emollient observing the same 
parameters. Effects on the skin barrier were determined by 
measuring skin barrier function, hydration, skin surface pH 
and by analysing Fourier transform infrared spectra before 
and after treatment. A third cohort of 6 young adults was re-
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acterized by reduced natural moisturizing factor [NMF, 
comprising sodium pyrrolidone carboxylic acid (PCA), 
urea and lactate amongst others] and abnormal levels of 
intercellular lipids (cholesterol, ceramides and free fatty 
acids) in the stratum corneum (SC)  [2–5] . Additionally, 
the aged skin barrier recovers more slowly after exposure 
to irritants  [6] .
 The growing recognition that xerotic skin conditions 
arise primarily as a result of a defective skin barrier calls 
for a greater appreciation of the effect of topical prod-
ucts on this barrier  [7, 8] . A paucity of evidence on the 
mechanistic effects of emollients has led many to believe 
that emollients are all the same. We, and others, have 
demonstrated however that emollients have very differ-
ent effects on the skin barrier depending on their formu-
lation  [9, 10] . For example, some optimally designed 
emollients containing humectants ameliorate skin dry-
ness and reduce the severity of skin inflammation  [11–
13] . In stark contrast, aqueous cream, containing the 
harsh anionic surfactant sodium lauryl sulphate (SLS) 
and no humectant, was found to damage the skin bar-
rier  [14–17] , an effect linked to high rates of adverse re-
actions and exacerbation of AD symptoms  [18] . In re-
sponse to growing evidence and improvements in emol-
lient formulation, a recent consensus statement by 
health care professionals highlighted the need to differ-
entiate emollients based on their mechanism of action 
 [19] . The aim of this study was to directly compare the 
effect of an emollient cream, available for prescription 
in the UK, containing the skin-moisturizing factors 
urea, ceramide NP (previously ceramide 3), and lactate 
(test emollient), to an emollient cream without these ad-
ditives (control emollient) in volunteers with xerosis 
aged over 60 years. 
 Material and Methods 
 Subjects 
 Three cohorts of volunteers were recruited. Volunteers scored 
their skin dryness on a 5-point scale from 1 (no dryness) to 5 (se-
vere dryness with cracking and lifting scales). Cohort 1 consisted 
of 21 volunteers (17 women) with dry skin (mean score 3) and a 
mean age of 69 (60–89) years. Eight participants (38%) reported 
previously having AD. Cohort 2 comprised 6 volunteers (4 wom-
en) with healthy skin (no history of skin conditions or atopy, mean 
skin dryness score 0) and a mean age of 33 (21–45) years. This 
separate population (cohort 2) with no age restriction was recruit-
ed for practical reasons due to the length of the measurement ses-
sions and the intensity of measurements. For cohort 3, 21 volun-
teers (14 women) with dry skin (mean score 3) and a mean age of 
68 (60–79) years were recruited, 18 of whom completed the study. 
Three volunteers withdrew for reasons unrelated to the study. Six 
participants (33%) reported a previous history of AD. Recruitment 
was open to males and females with a Fitzpatrick skin type of I–IV. 
Exclusion criteria consisted of the use of systemic or topical anti-
inflammatory medication in the 6 months leading up to the study, 
pregnancy, breast-feeding, and being under the age of 18. Volun-
teers refrained from using topical products (except the study prep-
aration as directed) on the treatment sites for  ≥ 7 days prior to 
participation and for the duration of the study. 
 Treatment  
 There were 2 test sites per volunteer, one on each forearm (vo-
lar side, 3 cm below elbow flexure to 3 cm above the wrist). Cohorts 
1 and 3 undertook 28-day forearm-controlled observer-blind 
studies involving self-treatment with the test emollient (Balneum 
cream,  table 1 ) and/or the control emollient (Aquamol cream,  ta-
ble 1 ). In essence cohort 1 undertook a direct comparison of the 
test emollient to untreated skin, and cohort 3 undertook a direct 
comparison of the test emollient to a reference emollient. The par-
ticipants in cohort 1 treated one forearm with 2-fingertip units 
(1.24 ± 0.127 g) of test emollient and the other forearm with no 
treatment (randomized) twice daily for 28 days. Following the ces-
sation of treatment (12–20 h) the biophysical properties of the test 
sites were assessed to determine the effect of the treatment on the 
underlying condition of the skin barrier (not their transient occlu-
 Table 1.  Emollient creams used in this study
Treatment Manufacturer Product pH Ingredients
Control 
emollient
Aquamol cream 
(Thornton & Ross Ltd., 
Huddersfield, UK)
5.57 ± 0.005 Purified water, white soft paraffin, liquid paraffin, 
cetearyl alcohol, PPG-5-ceteth 20, disodium 
cocoamphodiacetate, polysorbate 60, sodium 
chloride, chlorocresol, citric acid monohydrate
Test 
emollient
Balneum cream 
(Almirall Hermal GmbH, 
Reinbek, Germany)
4.73 ± 0.002 Urea 5%, ceramide NP, aqua, glycine soya oil, 
propylene glycol, cetearyl alcohol, liquid paraffin, 
isohexadecane, sodium lactate, lactic acid, PEG-20 
stearate, polysorbate 60, squalane, stearic acid, 
disodium EDTA, lecithin, tocopherol, ascorbyl 
palmitate, hydrogenated palm glyceride citrate
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sive properties). The participants in cohort 3 treated 1 forearm 
with 1.28 ± 0.126 g test emollient and the other forearm with 1.21 
± 0.120 g control emollient (randomized allocation) twice daily for 
28 days. Before initiation and after cessation (12–20 h following 
the last application) of treatment, the biophysical properties of the 
test sites were assessed. Cohort 2 undertook a forearm-controlled 
study wherein a single application of test emollient (2 fingertip 
units) was made to 1 test site. Assessments were performed before 
and 3 h following treatment application. 
 Biophysical Measurements 
 Transepidermal water loss (TEWL) measurements were per-
formed using an AquaFlux AF200 condensing chamber probe 
(Biox Systems Ltd., London, UK). Redness, capacitance and skin 
surface pH were measured using a Mexameter MX18, Corneo-
meter CM825 and Skin pH Meter PH905, respectively (CK elec-
tronic GmbH, Cologne, Germany). All assessments were per-
formed in a room maintained at 21 ± 2   °   C and 38–50% relative 
humidity according to published guidelines  [20] . All test sites were 
acclimatized to room conditions for 20 min before assessment. 
Tape-stripping, to experimentally disrupt the SC, was performed 
as previously described  [21] . Prior to tape-stripping the test sites 
were cleaned with cotton wool and water, and allowed to reaccli-
matize for 20 min. Extrapolation of depth reached by tape-strip-
ping was based on the infrared absorbance (SquameScan 850A, 
CuDerm, Dallas, Tex., USA) of tape strips (to quantify protein) in 
accordance with published methodology  [22, 23] .
 SC Protease Activity 
 Assessment of protease activity was made on samples compris-
ing 3 consecutive tape strips as previously described  [22] . Caseino-
lytic, chymotrypsin-like and trypsin-like activities were deter-
mined using EnzCheck ® (Life Technologies Ltd., Paisley, UK), 
MeOSuc-Arg-Pro-Tyr-AMC (Peptide Protein Research Ltd., 
Funtley, UK), and Boc-Phe-Ser-Arg-AMC (Bachem, Bubendorf, 
Switzerland) substrates, respectively. 
 Quantification of PCA and Lactate 
 The levels of PCA in SC samples collected by tape-stripping 
(strips 4–6 pooled) were quantified as previously described  [25] . 
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 Fig. 1. The effect of 28-day treatment with the test emollient (TE), 
compared to an untreated control (NTC), on skin surface pH ( a ), 
hydration ( b ), redness ( c ), TEWL ( d ) and SC integrity ( e ) 12–20 h 
following the last application in people with dry skin over the age 
of 60 (n = 21). Two-way ANOVA reported a significant effect of 
test emollient treatment (and the interaction between treatment 
and tape strip number) on SC integrity. Asterisks indicate signifi-
cant differences (p < 0.05) reported using the Holm-Sidak posttest 
following a one-way ANOVA ( a–d ) and Bonferroni posttest with 
 *  p < 0.05,  * * *  p < 0.001, and  * * * *  p < 0.0001 ( e ). 
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Lactate samples were collected using a prewetted cotton swab, 
which was rubbed against the skin and then transferred to 1 ml 
PBS. Lactate concentrations were determined using a fluorometric 
 L -lactate assay (Abcam, Cambridge, UK) according to the manu-
facturer’s instructions.
 Fourier Transform Infrared Spectroscopy 
 Fourier transform infrared (FTIR) spectra were collected us-
ing a silver halide fibre-optic probe (FTIR Flexispec PIR 900, Art 
Photonics, Berlin, Germany) attached to a Nicolet iS50 FTIR spec-
trometer (Thermo Fisher Scientific Inc., Waltham, Mass., USA), 
equipped with a cooled mercury-cadmium-telluride detector and 
purged with dry N 2 . An average of 32 scans was collected for each 
measurement at a resolution of 4 wave numbers. Integration of 
peak intensities was performed using Omnic 9.0 software (Ther-
mo Electron Corp., Madison, Wis., USA). Peak intensities in the 
spectral region from 4,000 to 2,000 cm –1 were normalized to the 
baseline at 3,800 cm –1 , and intensities in the region from 2,000 to 
1,000 cm –1 were normalized to the baseline at 1,850 cm –1 to ac-
count for contact pressure. The amount of water in the SC was 
determined by dividing the area of the peak at 3,300 cm –1 , encom-
passing the vibrations from the O–H of water and the N–H of 
proteins, by the area of the peak at 1,550 cm –1 , also relating to vi-
brations from N–H bonds. Lipid chain conformation was deter-
mined as previously described  [23] . Additional spectra were col-
lected from solutions of lactic acid, citric acid, PCA, and urea in 
water, mineral oil (liquid paraffin), and ceramide (mixture from 
bovine brain) in chloroform (Sigma-Aldrich, UK). The contribu-
tion of water or chloroform was removed by spectral subtraction 
of a water-only control.
 Data Analysis 
 The results were analysed by Prism v6.01 (Graphpad Software 
Inc., Calif., USA). The significance threshold was p < 0.05. Results 
are presented as means ± standard error of the mean.
 Results 
 Effect of the Test Emollient on the Skin Barrier 
 Treatment with the test emollient for 28 days signifi-
cantly reduced TEWL and skin surface pH by an average 
of 1.07 ± 0.29 g/m 2 /h and 0.15 ± 0.07 pH units compared 
to the untreated control site, respectively, in volunteers 
with dry skin aged >60 years, suggesting a positive effect 
on underlying skin barrier function ( fig.  1 ). Hydration 
was increased significantly (+2.09 ± 0.95 units) compared 
to the untreated control despite the last application being 
 ≥ 12 h previously. There was no effect of the treatment on 
skin redness, indicating that the test emollient is mild on 
aged skin under normal use conditions.
 To further assess the effect of the test emollient on the 
integrity of the SC, tape-stripping to experimentally dam-
age the SC in a controlled way was performed in conjunc-
tion with TEWL measurements ( fig. 1 e). TEWL consis-
tently increased at a reduced rate on the site treated with 
the test emollient with each consecutive 4 tape strips com-
pared to the untreated control suggesting a significantly 
increased SC integrity. The activity of extracellular prote-
ases involved in desquamation is an important determi-
nant of SC integrity. As such, we quantified broad-spec-
trum and peptide-specific activity in the superficial layers 
of the SC ( fig. 2 ). Broad-spectrum activity was significant-
ly reduced following treatment with the test emollient, as 
was chymotrypsin-like activity. Trypsin-like activity was 
also decreased, but not significantly. 
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 Fig. 2. The effect of 28-day treatment with the test emollient (TE) compared to an untreated control (NTC) on 
caseinolytic ( a ), chymotrypsin-like ( b ) and trypsin-like ( c ) protease activity. p values are the results of a paired
t test. 
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 Fig. 3. The effect of a single application of the test emollient on the 
biophysical properties of the skin: TEWL ( a ), skin surface pH ( b ), 
and hydration ( c ) before and 3 h following application.  d The con-
centration of water in the SC determined by FTIR spectroscopy 
before and 3 h following application. Measurements were collected 
in conjunction with tape-stripping to remove the uppermost layers 
of corneocytes and achieve greater depths. Two-way ANOVA re-
ported a significant effect of test emollient treatment (and the in-
teraction between treatment and tape strip number) on SC water 
content. AII = Amide II. * p < 0.05.  e Correlation between water 
concentration and capacitance (Pearson coefficient shown). Open 
circles correspond to measurements taken before treatment and 
filled circles to measurements taken after treatment. AII = Am-
ide II.  f The change in concentration of key functional groups
(3 h posttreatment subtracted by pretreatment measurements) 
throughout the SC as determined by FTIR.  g The position of the 
peak at 2,850 cm –1 , relating to the asymmetric stretching of CH 2 
lipid groups, throughout the depth of the SC. A two-way ANOVA 
reported no effect of treatment. ν as = Asymmetric stretching of the 
CH 2 bond of lipids; COG = centre of gravity.  h Example spectra 
collected before and after treatment. Regions identified on the 
spectra include: a = 3,300 cm –1 O–H of water; b = 2,920 and 2,850 
cm –1 CH 2 symmetric and asymmetric stretching of lipids; c = 1,740 
cm –1 lipid esters; d = 1,650 and 1,550 cm –1 relating to amide I and 
amide II; e = 1,465 cm –1 CH 2 scissoring of lipids; f = 1,410 cm –1 –
COO – carboxylates; g = 1,175 cm –1 N–H bending; h = 1,124 cm –1 
specific to lactate. 
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 The Short-Term Effects of the Test Emollient on SC 
Hydration 
 Having determined that 28 days of treatment with the 
test emollient exert positive effects on the underlying 
condition of the skin barrier, we next investigated the 
short-term emollient properties of the formulation. Three 
hours following a single application of the test emollient 
to the skin of adults <50 years of age with no skin com-
plaints (cohort 2), TEWL decreased and SC capacitance 
increased indicative of skin occlusion ( fig. 3 a, c). Skin sur-
face pH also decreased by 0.45 ± 0.075 units, and SC hy-
dration increased by 15.17 ± 2.40 units on average ( fig. 3 b). 
Using FTIR, the molecular properties of the skin surface, 
to a depth of 1.5 μm, were determined before and after 
treatment. Tape-stripping was employed to achieve a 
greater depth profile, spanning approximately 4.5 μm SC 
depth in total (assuming an SC density of 100 μg/μm 3 ). 
Overall there were a number of changes to the spectra col-
lected after treatment compared to before treatment, with 
the greatest changes observed at the skin surface ( fig. 3 h, 
without tape-stripping).
 The amount of water in the SC, based on absorbance 
at 3,300 cm –1 (corresponding to OH bond of water) was 
elevated throughout most of this depth following treat-
ment application ( fig. 3 d, significant to a depth of approx. 
2.74 μm based on measurement after removing 124.23 ± 
9.26 μm SC by tape-stripping). The mean intensity of the 
3,300 cm –1 band across the depth of the SC directly cor-
related (Pearson’s r = 0.785) with capacitance measure-
ments of SC hydration ( fig.  3 e, which measures across 
10–20 μm of the skin depth). Due to the reduced penetra-
tive depth of FTIR compared to capacitance measure-
ments, there is greater sensitivity for quantifying local-
ized surface changes in water content using the former 
method.
 Three hours following a single application of the test 
emollient, SC lipid levels were elevated, as indicated by 
the increased absorbance at 2,920 and 2,850 cm –1 corre-
sponding to symmetric and asymmetric CH 2 stretching 
of lipids. In the spectral region between 1,000 and 1,750 
cm –1 , there were further changes to the absorbance spec-
tra of the skin that matched the spectra of the test emol-
lient (online suppl. fig. 1a; for all online suppl. material, 
see www.karger.com/doi/10.1159/000445955). The ab-
sorbance spectrum of the test emollient is a composite of 
all its ingredients; the spectra of the major ingredients are 
presented in online supplementary figure 1b. The chang-
es in absorbance (after vs. before treatment) at specific 
spectral regions highlighted in online supplementary fig-
ure 1 have been presented in  figure 3 f. Absorbance is in-
creased at regions centered on: 1,740 cm –1 , correspond-
ing to lipid esters such as those in sebum and natural oils; 
1,650 cm –1 , corresponding to the C = O bond of proteins 
(amide I) for example; 1,540 cm –1 , corresponding to the 
N–H bond of proteins (amide II), ceramides and urea; 
1,410 cm –1 , corresponding to carboxylate groups 
(–COO); 1,175 cm –1 , corresponding to urea, and 1,124 
cm –1 , corresponding to lactate. No significant difference 
in the chain conformation of SC lipids as a result of these 
compositional changes was observed ( fig. 3 g).
 Effect of the Test Emollient Compared to an Emollient 
without Urea, Ceramide NP and Lactate on the Skin 
Barrier 
 Having determined that the test emollient delivers 
moisturizing factors to the SC, and that this corresponds 
with increased water levels in the skin, we sought to di-
rectly compare its effect to an emollient without these 
added moisturizing factors, the control emollient ( ta-
ble  1 ). The effect of 28 days of treatment with the test 
emollient compared to the control emollient on the bio-
physical properties of the skin of volunteers aged over 60 
years with self-reported dry skin is presented in  figure 4 
(cohort 3). There were no changes in skin redness indicat-
ing that neither formulation induces erythema under the 
conditions tested. Skin surface pH was significantly in-
creased on the site treated with the control emollient 
compared to the test emollient (+0.23 ± 0.05 units, p = 
0.0007) and compared to the baseline measurements 
(+0.30 ± 0.07 units, p = 0.0015). TEWL was unchanged 
following treatment with the test emollient (11.27 ± 0.19 
g/m 2 /h before and 11.58 ± 0.23 g/m 2 /h after). Following 
treatment with the control emollient, TEWL increased 
from 11.15 ± 0.23 to 11.94 ± 0.26 g/m 2 /h (p <  0.01) sug-
gesting a small reduction in skin barrier function. More-
over, the integrity of the SC was significantly decreased at 
the site treated with the control emollient, indicated by 
elevated TEWL throughout tape-stripping ( fig. 4 e), when 
compared to both pretreatment assessments of the test 
area (adjacent test site) and the sites treated with the test 
emollient at the same time point. 
 Because the emollients differentially affected SC integ-
rity and skin surface pH, assessment of SC proteolytic ac-
tivity was also performed ( fig. 5 ). In line with cohort 1, the 
test emollient reduced broad-spectrum activity by 0.36 ± 
0.16 nU/μg compared to the control emollient, which ex-
hibited similar activity compared to the untreated sites in 
cohort 1 ( fig. 2 a). There was no difference in chymotryp-
sin-like activity between the test and control emollient-
treated sites, suggesting that both treatments inhibit this 
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activity (see also  fig. 2 b). Trypsin-like activity was signif-
icantly increased by 1.20 ± 0.59 nU/μg on the sites treated 
with the control compared to the test emollient, which 
exhibited similar activity to untreated skin ( fig. 2 c). Ele-
vated proteolytic activity is therefore a potential mecha-
nism by which SC integrity is reduced following treat-
ment with the control emollient.
 Skin hydration increased by 12.2 ± 5.40% following 
treatment with the test emollient and 6.6 ± 3.51% follow-
ing treatment with the control (12–20 h following last ap-
plication); however, the increase was only significant for 
the test emollient ( fig. 4 ). To better understand how the 
emollients alter hydration, levels of two NMF components 
in the SC were quantified ( fig. 6 ). Lactate is readily detect-
able in superficial skin samples and was used as a marker 
for the delivery of exogenous moisturizing factors from 
the test emollient. PCA, not present in either of the for-
mulations tested, is a useful biomarker for total filaggrin-
derived NMF components and was employed to deter-
mine the effect of the treatments on endogenous moistur-
izing factor levels  [24] . Lactate was significantly elevated 
(by 57% on average) in the SC of test emollient- but not 
control emollient-treated skin >12 h following the last ap-
plication. The amount of lactate in the skin was also found 
to significantly correlate with skin surface pH, helping ex-
plain the difference in skin surface pH between the sites 
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 Fig. 4. The effect of 28-day treatment with the test emollient, com-
pared to the control emollient on skin surface pH ( a ), hydration 
( b ), redness ( c ), skin barrier function ( d ) and SC integrity ( e ) 12–
20 h following the last application in people with dry skin over the 
age of 60 (n = 18). For  a–d , a one-way ANOVA found significant 
differences between the groups for TEWL (p = 0.0018), hydration 
(p = 0.0026) and skin surface pH (p = 0.0002). Asterisks indicate 
the results of a Bonferroni posttest:  *  p <  0.05,  * *  p <  0.01,  * * *  p < 
0.001.  e SC integrity is displayed as the change from baseline 
(TEWL after – TEWL before ). A two-way ANOVA reported a signifi-
cant difference between the test and control emollient-treated 
sites. Asterisks indicate the results of a Bonferroni posttest:  * * *  p < 
0.001,  * * * *  p < 0.0001. 
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 Fig. 5. The effect of 28-day treatment with the test emollient compared to the control emollient on caseinolytic 
( a ), chymotrypsin-like ( b ) and trypsin-like ( c ) protease activity. Asterisks indicate the results of a paired t test: 
 *  p < 0.05. 
 Fig. 6. The effect of 28-day treatment with the test emollient com-
pared to the control emollient on lactate levels quantified from skin 
swabs ( a ), PCA levels quantified from tape strip samples ( c ), FTIR-
determined lactate levels based on absorbance at 1,124 cm –1 ( e ), 
and FTIR-determined carboxylic acid levels based on absorbance 
at 1,410 cm –1 /amide II ( g ) 12–20 h following the last application in 
people with dry skin over the age of 60 (n = 18). A one-way ANOVA 
found significant differences between the groups for lactate (p = 
0.0154), PCA (p = 0.0002), 1,124 cm –1 (p = 0.0275), and 1,410 
cm –1 /amide II (p  ≤ 0.0001). Asterisks indicate the results of a Bon-
ferroni posttest:  *  p < 0.05. Correlations between the parameters 
and biophysical measurements are presented in  b ,  d ,  f , and  h .  
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treated with the test and control emollients ( fig. 6 b). In-
terestingly PCA was also significantly elevated (by 43%) 
following treatment with the test emollient but not the 
control emollient, suggesting that treatment with the test 
emollient promotes endogenous NMF production (PCA 
not present in either topical formulation). The levels of 
PCA were correlated with skin barrier function ( fig. 6 d).
 FTIR spectroscopy was conducted at the skin surface 
and following 3 consecutive tape strips to determine the 
molecular properties of the skin to a depth of 0–1.5 μm 
and to a depth of 0.56–2.06 μm, respectively (based on the 
removal of 55.71 ± 2.35 μm protein by tape-stripping – no 
difference between the protein removed from the test 
sites was found using a one-way ANOVA). Example ab-
sorbance spectra of the skin before and after treatment are 
presented in online supplementary figure 2, and the mean 
changes in the spectral features identified are detailed in 
online supplementary table 1. The amount of water in the 
skin increased significantly on the sites treated with the 
test emollient but remained unchanged on the sites treat-
ed with control emollient. The amount of lipid (vCH 2 and 
δCH 2 ) groups on and within the skin increased signifi-
cantly on both the test and control emollient-treated sites. 
In contrast, the intensity of the peaks at 1,740 cm –1 (lipid 
esters), 1,650 cm –1 (amide I), 1,550 cm –1 (amide II), 1,410 
cm –1 (carboxyl group), 1,175 cm –1 (urea), and 1,124 cm –1 
(lactate) are all significantly higher on the sites treated 
with the test emollient compared to the control emollient. 
Each of the peaks relates to specific molecular bonds, as 
opposed to specific compounds, so it is not possible to 
determine the changes in specific skin components. The 
intensity of the peak at 1,124 cm –1 , relating to lactate, did 
correlate with lactate levels quantified from the skin sam-
ples ( fig. 6 e, f). The peak at 1,410 cm –1 corresponding to 
the carboxyl group of skin humectants, including PCA, is 
also contributed to by ceramides and urea. When nor-
malized to the amide II peak, to enrich for carboxylic ac-
ids (i.e. to remove the contribution of molecules contain-
ing the N–H group such as ceramides and urea), the in-
tensity of the peak at 1,410 cm –1 correlates well with PCA 
levels quantified in the skin ( fig. 6 h). In agreement with 
HPLC-derived PCA levels, a significant increase in car-
boxylic acids was indicated by the change in the 1,410 
cm –1 /amide II ratio following treatment with the test 
emollient ( fig.  6 g). Increases in ceramide, urea and/or 
protein levels following treatment with the test emollient 
are also suggested by the increase in amide I and 1,175 
cm –1 peak intensities. Notably treatment with the control 
emollient actually reduced the levels of amide bonds 
within the SC, most likely because the ceramide, urea 
and/or protein fraction of the SC had been displaced by 
the increase in lipids.
 To determine whether changes in carboxylic acid and 
ceramide/urea/protein levels affect skin hydration, they 
were correlated with capacitance measurements ( fig. 7 ). 
The 1,410 cm –1 /amide II ratio correlated weakly with ca-
pacitance and strongly with FTIR-determined SC water 
content. The lower correlation with capacitance can be 
linked to the different penetration depths of the tech-
niques. Following treatment with the test emollient, 
where changes in water and carboxylic acid levels occur 
predominantly in the uppermost layers of the SC from 
where FTIR measurements are gathered, the correlation 
with capacitance improved. A significant correlation be-
tween amide II peak intensities and capacitance or FTIR 
SC water content was not observed.
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 Discussion 
 The finding that aqueous cream BP damages the skin 
barrier highlighted the need to better understand the effect 
of emollients on the skin  [15, 18] . In contrast to aqueous 
cream, the test emollient, after 28 days of treatment, im-
proved skin barrier function (decreased TEWL) and SC 
integrity compared to an untreated control in volunteers 
with dry skin aged over 60 years. The negative effects of 
aqueous cream have been attributed to the use of SLS as an 
emulsifier  [17, 25] . SLS is a standard skin irritant, eliciting 
multiple negative effects on the skin including elevation of 
skin surface pH and reduction in skin barrier function (el-
evated TEWL)  [26] . The use of relatively (relative to SLS) 
milder non-ionic surfactants with reduced irritant poten-
tial likely contributes to the improved effect of the test 
emollient  [27] . These same beneficial effects were not ob-
served when the control emollient, also formulated with 
milder (relative to SLS) surfactants, was used to treat dry 
skin for 28 days. Whilst not as damaging as aqueous cream, 
the control emollient was associated with elevated TEWL 
and reduced SC integrity. The response of participants 
with a history of AD (33%) was different to those without 
a history of AD; however, the size of the subgroups was not 
large enough to permit a proper subgroup analysis. Never-
theless, evidence already shows that individuals with a his-
tory of AD are more prone to skin barrier damage from 
topical products  [15, 17] . Neither treatment adversely af-
fected lipid chain conformation determined by FTIR  [23] ; 
however, the control emollient was associated with signif-
icantly elevated skin surface pH and protease activity com-
pared to the test emollient. A pH-induced elevation of pro-
tease activity is an established mechanism of skin barrier 
breakdown, characterized by degradation of corneodes-
mosomal junctions in the SC  [28] . The differential effect of 
the treatments on SC pH and protease activity may there-
fore explain the different effects of the treatments on skin 
barrier function and SC integrity. 
 Whilst the surfactant/emulsification system employed 
could account for the elevation of skin surface pH follow-
ing treatment with the control emollient, it is unlikely to 
account for the reduction in skin surface pH brought 
about by the test emollient. The long-term reduction of 
skin surface pH using topical treatments has recently 
been found to improve both skin barrier function and 
hydration, in agreement with the results presented here 
 [29] . Skin surface pH is regulated via several mechanisms, 
e.g. by the generation of acidic natural moisturizing fac-
tors such as urocanic acid and lactic acid  [30, 31] . The 
skin surface pH of the subjects recruited in this study dis-
played a significant direct relationship with the level of 
lactate in the skin. Moreover treatment with the test 
emollient, unlike with the control emollient, elevated lac-
tate levels in the skin for more than 24 h following the last 
application. Aged skin contains significantly reduced lev-
els of some carboxylates, including lactate and PCA, 
which may account for the elevated skin surface pH and 
propensity for xerosis  [5, 32, 33] . It is interesting there-
fore that the test emollient maintains skin surface pH by 
replenishing the carboxylate pool. 
 The greatest difference between the emollients tested 
was their effect on hydration. While the control emollient 
was poorly hydrating, the test emollient imparted clini-
cally relevant levels of elevated hydration (similar in scale 
to the difference in hydration between healthy and AD 
skin  [34, 35] ) for more than 24 h after cessation of treat-
ment. The increase in hydration outlasted the transient 
occlusive effect of the cream and can therefore be attrib-
uted to an increased ability of the SC to hold onto mois-
ture. Humectants, including urea and lactate found in the 
test emollient, are naturally present in the SC and contrib-
ute to its water-holding capacity  [5] . Ceramide, also pres-
ent in the test cream, is a component of the lipid matrix 
that contributes to SC permeability barrier function  [36] . 
Emollients containing ceramide NP have been shown to 
both hydrate the skin and improve TEWL  [37] . Following 
treatment with the test but not the control emollient, sig-
nificant increases in the levels of humectants and natural 
skin lipids were observed by FTIR spectroscopy. Using 
this technique it was not possible to distinguish between 
specific compounds; however, the SC pool of carboxylic 
acids and the combined levels of urea, ceramides, and 
protein increased significantly following a single applica-
tion of the test emollient and remained elevated for at 
least 24 h after a 28-day treatment regimen. The carboxyl-
ate pool in particular was significantly correlated with the 
increased water-holding capacity of the skin. Urea is the 
predominant humectant in the test emollient and so also 
likely accounts for a significant proportion of the SC’s 
improved water-holding capacity  [38] . The hydrating ef-
fect of urea has been demonstrated in a range of bases 
previously (reviewed in Pan et al.  [39]  and Loden [40] ). 
 While humectants like urea and lactate have very pos-
itive effects on the skin, excessive hydration caused by 
excessive humectant levels can lead to enhanced proteo-
lytic degradation of the SC  [41, 42] , indicating that the 
correct humectant concentration is crucial to barrier re-
pair. We observed no reduction in SC integrity in con-
junction with decreased protease activity, indicating that 
an appropriate urea concentration was used to balance 
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positive and negative effects in this study population. The 
combination with lactic acid maintaining skin surface pH 
may contribute to the overall positive effect observed in 
this regard  [43] .
 In addition to imparting skin moisturization, urea has 
recently been shown to significantly improve skin barrier 
function in healthy volunteers when applied once daily 
for 4 weeks in a 20% cream preparation  [44] . This im-
provement was associated with the elevated expression of 
genes involved in SC homeostasis, including the  FLG 
gene encoding filaggrin. A 10% urea preparation in-
creased  FLG expression to the same extent. Concentra-
tions less than 10% were not tested in this particular 
study; however, formulations containing 5% urea have 
been shown to strengthen the skin barrier in a series of 
other studies  [45, 46] . Moreover the barrier-strengthen-
ing properties of the emollients were linked to the ability 
of the emollients to delay relapses of both AD and hand 
eczema in young adults  [13, 47–49] . The results of this 
study further demonstrate that a distinct 5% urea prepa-
ration with ceramide NP and lactate also imparts positive 
effects on skin barrier function and SC integrity in an old-
er population. In addition, a significant rise in PCA levels, 
a product of filaggrin catabolism, in the SC following 
treatment with the test emollient (which does not contain 
PCA) but not the control emollient was observed. PCA 
levels tend to coincide with urocanic acid and free amino 
acid levels, because they are all derived from filaggrin 
breakdown  [24] . TEWL was also found to correlate with 
PCA levels in this study, in line with the relationship be-
tween filaggrin levels and TEWL. Given that PCA is not 
an ingredient of the emollients tested, this finding sup-
ports the ability of topical urea preparations to induce 
filaggrin gene expression, when formulated into a pre-
scription emollient at 5%. Moreover, it demonstrates that 
this increase in expression leads to increased filaggrin lev-
els and subsequently increased NMF levels. This new 
finding further reinforces the potential barrier-strength-
ening properties of emollient creams. In addition the lev-
el of lactate, a non-filaggrin-derived NMF component, 
was also specifically increased following treatment with 
the test emollient. Lactate elicits biological effects on the 
skin, resulting in enhancement of lipid synthesis, and as 
such may contribute to the positive effects of the test 
emollient on skin barrier homeostasis  [50] . 
 The test emollient also contains ceramide NP, a com-
ponent of the lipid lamellae. Ceramides, the levels of 
which decrease with advancing age, are essential for op-
timum lipid structure and permeability barrier function 
 [3, 23, 51] . In this study we were unable to specifically 
show whether ceramide NP was taken up by the skin due 
to the overlapping spectral profiles of ceramides, urea and 
protein. Lipid esters were elevated following treatment 
with the test emollient; however, their penetration was 
limited. Sebum is a source of triglycerides (lipid esters) on 
the skin surface, and its production was found to decline 
in women with advancing age  [52] . The level of total lip-
ids, which includes non-physiological lipids (of white soft 
paraffin and liquid paraffin), increases significantly fol-
lowing treatment with both topical emollients. The com-
bination of lipid changes following treatment with the 
test emollient did not appear to affect lipid chain confor-
mation; however, it remains possible that the physiologi-
cal lipids, such as ceramide NP, contributed to the de-
crease in TEWL and improvement in SC integrity found 
following treatment with the test emollient  [37, 50] . With 
respect to SC hydration, the relative proportion of mois-
turizing factors to lipids was important, wherein the size 
of the carboxylate pool was linked to SC water content.
 Taken together, the added humectants (lactate and 
urea) and the increased levels of endogenously produced 
humectants (PCA) are important in imparting the sig-
nificant increase in skin hydration following treatment 
with the test emollient and for the reduction of skin sur-
face pH and improvement in the structure and function 
of the skin barrier. Importantly the levels of these metab-
olites are depleted in aged and xerotic skin, and correlate 
with the severity of xerotic skin conditions such as AD  [5, 
24, 53, 54] . Low NMF levels associated with an  FLG gene 
mutation are a major risk factor for the development of 
AD, and by extension also asteatotic eczema  [1, 55, 56] . 
The test emollient therefore addresses an important path-
ological process in xerotic skin conditions, setting it apart 
from emollients without humectants and skin lipids like 
the control emollient tested here. 
 In conclusion, the test emollient (containing 5% urea, 
ceramide NP and lactate) significantly hydrated the skin 
to a greater extent, and for a longer period of time, com-
pared to an emollient containing no skin-moisturizing 
factors, and imparted additional benefits to the structure 
and function of the skin barrier. As such there is a con-
vincing rationale for differentiating emollients based on 
their composition of SC constituents  [19] . In this case the 
test emollient was well tolerated in people with dry skin 
aged over 60 years and addressed the pathological features 
of dry skin, supporting a role for this class of emollient as 
a first-line treatment for xerotic skin conditions in the 
aged population. The structural/biophysical and biologi-
cal (enhanced  FLG expression) effects of urea and lactate 
in the test emollient, and combination of natural skin lip-
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ids, mean that generalizability with other humectant 
emollients is tenuous  [57] . As such an evidence-based ap-
proach is always recommended for selecting emollients, as 
not all emollient cream formulations are the same.
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